Compare Medpace Holdings Inc (MEDP) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs M&T Bank Corporation — how do they compare? Medpace Holdings Inc trades at $534.38 (market cap $15.08B), while M&T Bank Corporation trades at $247.94 (market cap $36.15B). The key difference: M&T Bank Corporation is far larger — about 2.4× Medpace Holdings Inc's market cap, and M&T Bank Corporation pays a 2.41% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MTB | |
|---|---|---|
Market Cap | $15.08B | $36.15B |
Sector | Technology | Financials |
52-Week High | $620.59 | $254.04 |
52-Week Low | $308.88 | $178.63 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
M&T Bank (MTB) trades at $249.54, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 13.19 and net income margin of 30.85%, supported by robust loan growth and net interest income as highlighted in Q2 2026 results. Analyst consensus is a buy with a $253.68 price target, though the majority of ratings are hold.
The outlook for MTB is positive due to solid earnings performance and healthy credit quality, but risks include elevated costs and macroeconomic pressures. Investment opportunity lies in its valuation and dividend yield, while investors should monitor expense management and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
